These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8740979)

  • 1. Circulating immune markers in advanced renal cell carcinoma during immunotherapy with interferon gamma.
    Höbarth K; Hallas A; Steiner G; Gomahr A; Aulitzky W; Marberger M
    Urol Res; 1996; 24(2):101-6. PubMed ID: 8740979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue polypeptide-specific antigen in renal cell carcinoma.
    Höbarth K; Hallas A; Kramer G; Aulitzky W; Gomahr A; Steiner G; Marberger M
    Eur Urol; 1996; 30(1):89-95. PubMed ID: 8854074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and significance of serum sICAM-1 and sCD4 & sCD8 in patients with nasopharyngeal carcinoma].
    Wang L; Shu M; Wei Q; Xiang J
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Nov; 16(11):596-8. PubMed ID: 15515547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifications of general parameters of immune activation in the sera of Sicilian patients with Boutonneuse fever.
    Mansueto S; Vitale G; Mocciaro C; Gambino G; Colletti P; Mansueto P; Spinelli A; Affronti M; Chifari N; Arcoleo F; Milano S; Cillari E
    Clin Exp Immunol; 1998 Mar; 111(3):555-8. PubMed ID: 9528898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of soluble CD8 and CD4 in patients with infectious mononucleosis.
    Yoneyama A; Nakahara K; Higashihara M; Kurokawa K
    Br J Haematol; 1995 Jan; 89(1):47-54. PubMed ID: 7833276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis: comparison of immunological markers in patients with acute and remission phase.
    De Pità O; Ruffelli M; Cadoni S; Frezzolini A; Biava GF; Simom R; Bottari V; De Sanctis G
    J Dermatol Sci; 1996 Nov; 13(2):118-24. PubMed ID: 8953411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma.
    Hoffmann R; Franzke A; Buer J; Sel S; Oevermann K; Duensing A; Probst M; Duensing S; Kirchner H; Ganser A; Atzpodien J
    Br J Cancer; 1999 Apr; 79(11-12):1742-5. PubMed ID: 10206286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy].
    Modelska-Ziółkiewicz A; Gembicki M; Bednarek J; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis.
    Schriefer A; Barral A; Carvalho EM; Barral-Netto M
    Clin Exp Immunol; 1995 Dec; 102(3):535-40. PubMed ID: 8536369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of serum levels of soluble CD4, CD8 and beta 2-microglobulin in visceral human leishmaniasis.
    Vitale G; Mocciaro C; Malta R; Gambino G; Spinelli A; Giordano C; Stassi G; Arcoleo F; Milano S; Cillari E
    Clin Exp Immunol; 1994 Aug; 97(2):280-3. PubMed ID: 8050177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses.
    Aulitzky W; Gastl G; Aulitzky WE; Nachbaur K; Lanske B; Kemmler G; Flener R; Frick J; Huber C
    Immunobiology; 1987 Dec; 176(1-2):85-95. PubMed ID: 3129362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.
    Aulitzky W; Gastl G; Aulitzky WE; Herold M; Kemmler J; Mull B; Frick J; Huber C
    J Clin Oncol; 1989 Dec; 7(12):1875-84. PubMed ID: 2511277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
    Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
    Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity.
    Coll-Vinent B; Vilardell C; Font C; Oristrell J; Hernández-Rodríguez J; Yagüe J; Urbano-Márquez A; Grau JM; Cid MC
    Ann Rheum Dis; 1999 Mar; 58(3):189-92. PubMed ID: 10364919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in soluble CD4 and CD8 proteins in healthy pregnant and postpartum women.
    Watanabe M; Iwatani Y; Hidaka Y; Mitsuda N; Amino N
    Am J Reprod Immunol; 1996 Oct; 36(4):220-7. PubMed ID: 8911630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.
    Spronk PE; ter Borg EJ; Huitema MG; Limburg PC; Kallenberg CG
    Ann Rheum Dis; 1994 Apr; 53(4):235-9. PubMed ID: 8203951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intercellular adhesion molecule 1 (ICAM-1) and insulinlike growth factor 1 (IGF-1) in patients with renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Investig Urol (Berl); 1994; 5():51-4. PubMed ID: 7719320
    [No Abstract]   [Full Text] [Related]  

  • 19. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
    De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.